Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1α-hydroxyvitamin D5

Journal of the National Cancer Institute

Volumn 89, Issue 3, 1997, Pages 212-218

  Mehta, Rajendra G ^a   Moriarty, Robert M ^b   Mehta, Rajeshwari R ^a   Penmasta, Raju ^b   Lazzaro, Gianluca ^a   Constantinou, Andreas ^a   Guo, Liang ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA HYDROXYVITAMIN D5; 24 ETHYLCHOLECALCIFEROL; CALCITRIOL; COLECALCIFEROL DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; NONHUMAN; RAT;

EID: 0031034110     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.3.212     Document Type: Article

References (34)

1. Bell NH. Vitamin D-endocrine system. J Clin Invest 1985;76:1-6.
2. Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, et al. Molecular biology of the vitamin D hormone. Recent Prog Hormone Res 1988;44:263-305.
3. DeLuca HF. New concepts of vitamin D functions. Ann N Y Acad Sci 1992;669:59-68.
4. Henry HL, Norman AW. Vitamin D metabolism and biological action. Ann Rev Nutr 1989;4:493-525.
5. 3, inhibits the growth of human breast cancer cells in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832-7.
6. 3 receptors and action in human prostate cell lines. Endocrinology 1992;132:1952-8.
7. 3. Proc Natl Acad Sci U S A 1981;78:4990-4.
8. 3 and skin diseases. Arch Dermatol Res 1992;284 Suppl 1:S30-6.
9. DeLuca HF. The metabolism and functions of vitamin D. Adv Exp Med Biol 1986;196:361-75.
10. Bouillon R, Okamura WH, Norman AW. Structure-function relationship in the vitamin D endocrine system. Endocrine Rev 1995;16:200-57.
11. Mehta RG, Steele V, Kelloff GJ, Moon RC. Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res 1991;11:587-91.
12. Dickens MS, Custer RP, Sorof S. Retinoid prevents mammary gland transformation by carcinogenic hydrocarbon in whole-organ culture. Proc Natl Acad Sci U S A 1979;76:5891-5.
13. Chatterjee M, Banerjee MR. Influence of hormones on N-(4-hydroxyphenyl) retinamide inhibition of 7,12-dimethylbenz[α]anthracene transformation of mammary cells in organ culture. Cancer Lett 1982;16:239-45.
14. Lin FK, Banerjee MR, Crump LR. Cell cycle-related hormone carcinogen interaction during chemical carcinogen induction of nodule-like mammary lesions in organ culture. Cancer Res 1976;36:1607-14.
15. Telang NT, Banerjee MR, Iyer AP, Kundu AB. Neoplastic transformation of epithelial cells in whole mammary gland in vitro. Proc Natl Acad Sci U S A 1979;76:5886-90.
16. Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995;16:399-404.
17. Carlberg C, Bendik I, Wyss A, Meir E, Sturzenbecker LJ, Grippo JF, et al. Two nuclear signalling pathways for vitamin D. Nature 1993;361:657-60.
18. 3 on thyrotropin-induced iodide uptake. Mol Cell Endocrinol 1991;81:25-31.
19. Lawson DE, Muir E. Molecular biology and vitamin D function. Proc Nutr Soc 1991;50:131-7.
20. Ozono K, Liao J, Kerner SA, Scott RA, Pike JW. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J Biol Chem 1990;265:21881-8.
21. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
22. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55:2822-30.
23. 3 receptors: structure and function in transcription. Annu Rev Nutr 1991;11:189-216.
24. Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M. Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. J Cell Sci Suppl 1990;13:139-48.
25. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48: 417-28.
26. Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, et al. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res 1995;55:2380-6.
27. Roberts AB, Kim SJ, Kondaiah P, Jakowlew SB, Denhez F, Glick AB, et al. Transcriptional control of expression of the TGF-βs. Ann N Y Acad Sci 1990;593:43-50.
28. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653-6.
29. Silberstein GB, Daniel CW. Reversible inhibition of mammary gland growth by transforming growth factor-β. Science 1987;237:291-3.
30. 3 and related compounds. J Org Chem 1980;45:3253-8.
31. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
32. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 1991;2:475-80.
33. Massague J, Cheifetz S, Ignotz RA, Boyd FT. Multiple type-beta transforming growth factors and their receptors. J Cell Physiol 1987;Suppl 5: 43-7.
34. Wakefield LM, Letterio JJ, Geiser AG, Flanders KC, O'Shaughnessy J, Roberts AB, et al. Transforming growth factor-betas in mammary tumorigenesis: promoters or antipromoters? Prog Clin Biol Res 1995;391:133-48.